Cancer stem cell (SC) chemoresistance may be responsible for the poor clinical outcome of non-small-cell lung cancer (NSCLC) patients. In order to identify the molecular events that contribute to NSCLC chemoresistance, we investigated the DNA damage response in SCs derived from NSCLC patients. We found that after exposure to chemotherapeutic drugs NSCLC-SCs undergo cell cycle arrest, thus allowing DNA damage repair and subsequent cell survival. Activation of the DNA damage checkpoint protein kinase (Chk) 1 was the earliest and most significant event detected in NSCLC-SCs treated with chemotherapy, independently of their p53 status. In contrast, a weak Chk1 activation was found in differentiated NSCLC cells, corresponding to an increased sensitivity to chemotherapeutic drugs as compared with their undifferentiated counterparts. The use of Chk1 inhibitors in combination with chemotherapy dramatically reduced NSCLC-SC survival in vitro by inducing premature cell cycle progression and mitotic catastrophe. Consistently, the co-administration of the Chk1 inhibitor AZD7762 and chemotherapy abrogated tumor growth in vivo, whereas chemotherapy alone was scarcely effective. Such increased efficacy in the combined use of Chk1 inhibitors and chemotherapy was associated with a significant reduction of NSCLC-SCs in mouse xenografts. Taken together, these observations support the clinical evaluation of Chk1 inhibitors in combination with chemotherapy for a more effective treatment of NSCLC. © 2012 Macmillan Publishers Limited. All rights reserved.

Bartucci, M., Svensson, S., Romania, P., Dattilo, R., Patrizii, M., Signore, M., Navarra, S. M., Lotti, F., Biffoni, M., Pilozzi, E., Duranti, E., Martinelli, S., Rinaldo, C., Zeuner, A., Maugeri-Saccà, M., Eramo, A., De Maria Marchiano, R., Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy, <<CELL DEATH AND DIFFERENTIATION>>, 2012; 19 (5): 768-778. [doi:10.1038/cdd.2011.170] [http://hdl.handle.net/10807/112175]

Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy

Navarra, Simone Maria;De Maria Marchiano, Ruggero
2012

Abstract

Cancer stem cell (SC) chemoresistance may be responsible for the poor clinical outcome of non-small-cell lung cancer (NSCLC) patients. In order to identify the molecular events that contribute to NSCLC chemoresistance, we investigated the DNA damage response in SCs derived from NSCLC patients. We found that after exposure to chemotherapeutic drugs NSCLC-SCs undergo cell cycle arrest, thus allowing DNA damage repair and subsequent cell survival. Activation of the DNA damage checkpoint protein kinase (Chk) 1 was the earliest and most significant event detected in NSCLC-SCs treated with chemotherapy, independently of their p53 status. In contrast, a weak Chk1 activation was found in differentiated NSCLC cells, corresponding to an increased sensitivity to chemotherapeutic drugs as compared with their undifferentiated counterparts. The use of Chk1 inhibitors in combination with chemotherapy dramatically reduced NSCLC-SC survival in vitro by inducing premature cell cycle progression and mitotic catastrophe. Consistently, the co-administration of the Chk1 inhibitor AZD7762 and chemotherapy abrogated tumor growth in vivo, whereas chemotherapy alone was scarcely effective. Such increased efficacy in the combined use of Chk1 inhibitors and chemotherapy was associated with a significant reduction of NSCLC-SCs in mouse xenografts. Taken together, these observations support the clinical evaluation of Chk1 inhibitors in combination with chemotherapy for a more effective treatment of NSCLC. © 2012 Macmillan Publishers Limited. All rights reserved.
2012
Inglese
Bartucci, M., Svensson, S., Romania, P., Dattilo, R., Patrizii, M., Signore, M., Navarra, S. M., Lotti, F., Biffoni, M., Pilozzi, E., Duranti, E., Martinelli, S., Rinaldo, C., Zeuner, A., Maugeri-Saccà, M., Eramo, A., De Maria Marchiano, R., Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy, <<CELL DEATH AND DIFFERENTIATION>>, 2012; 19 (5): 768-778. [doi:10.1038/cdd.2011.170] [http://hdl.handle.net/10807/112175]
File in questo prodotto:
File Dimensione Formato  
Therapeutic targeting of Chk1 in NSCLC.pdf

accesso aperto

Tipologia file ?: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 1.04 MB
Formato Adobe PDF
1.04 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/112175
Citazioni
  • ???jsp.display-item.citation.pmc??? 68
  • Scopus 143
  • ???jsp.display-item.citation.isi??? 132
social impact